Showing 1341-1350 of 1511 results for "".
- COVID-19 Vaccine Developers Seek to Reassure Public Over Safetyhttps://modernod.com/news/covid-19-vaccine-developers-seek-to-reassure-public-over-safety/2478249/Sources suggested that a number of drugmakers, including GlaxoSmithKline, Johnson & Johnson and Pfizer, are planning to release a statement outlining their commitment to only seek FDA approval of a vaccine against COVID-19 if it is supported by extensive safety and efficacy data. The move is
- J&J Looking to Enroll 60,000 Participants in Coronavirus Vaccine Trialhttps://modernod.com/news/jj-looking-to-enroll-60000-participants-in-coronavirus-vaccine-trial/2478185/A phase 3 trial Johnson & Johnson is planning to get under way in September to test its coronavirus vaccine candidate Ad26.COV2.S is looking to recruit up to 60,000 participants globally, the company confirmed Thursday. The targeted enrollment, first reported on the ClinicalTrials.gov databas
- EU Wraps Up Exploratory Talks With J&J to Secure Coronavirus Vaccinehttps://modernod.com/news/eu-wraps-up-exploratory-talks-with-jj-to-secure-coronavirus-vaccine/2478163/The European Commission said that it concluded exploratory talks with Johnson & Johnson to buy Ad26.COV2.S, the company’s vaccine candidate against COVID-19. Under the potential deal, once a vaccine has shown to be safe and effective against the novel coronavirus, the Commission s
- J&J Vaccine Protects Monkeys From Covid With Single Shothttps://modernod.com/news/jj-vaccine-protects-monkeys-from-covid-with-single-shot/2478099/Johnson & Johnson’s experimental coronavirus vaccine protected a group of macaques with a single shot in an early study, prompting the U.S. drugmaker to start trials in humans this month, according to a Bloomberg
- J&J Eyes Late-Stage Study Start of COVID-19 Vaccine in Septemberhttps://modernod.com/news/jj-eyes-late-stage-study-start-of-covid-19-vaccine-in-september/2478037/Johnson & Johnson disclosed alongside its second-quarter earnings call on Thursday that it hopes to begin a late-stage study of its COVID-19 vaccine candidate Ad26.COV2-S in late September, ahead of its previous schedule. The company is in talks with the US National Institutes of Health to br
- Interim 6-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosahttps://modernod.com/news/interim-6-month-data-of-rpgr-gene-therapy-shows-significant-vision-improvement-in-patients-living-with-x-linked-retinitis-pigmentosa/2478036/The Janssen Pharmaceutical Companies of Johnson & Johnson announced 6-month data from the ongoing phase 1/2 trial of its investigational gene therapy for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). The interim data showed that low and intermediate doses of
- Gil Kliman, MD, and Tom Frinzi Appointed to STAAR Surgical Board of Directorshttps://modernod.com/news/gil-kliman-md-and-tom-frinzi-appointed-to-staar-surgical-board-of-directors/2477846/Staar Surgical announced the appointment of Gilbert H. Kliman, MD, Managing Partner, InterWest Partners, and Thomas G. Frinzi, former Worldwide President, Surgical, Johnson & Johnson Vision, to its board of directors, effective June 1, 2020. The appointment of Dr. Kliman and Mr. Frinzi brings
- CXL Ophthalmics Appoints Jonathan H. Talamo, MD, to its Board of Managershttps://modernod.com/news/cxl-ophthalmics-appoints-jonathan-h-talamo-md-to-its-board-of-managers/2477675/CXL Ophthalmics announced the appointment of Jonathan H. Talamo, MD, to its Board of Managers. Dr. Talamo was most recently Chief Medical Officer and Worldwide Vice President of Clinical and Medical Affairs at Johnson and Johnson Vision. While at Johnson and Johnson Vision, Dr. Talamo hel
- EMA Grants Two Product Designations to Janssen’s RPGR Gene Therapy for X-Linked Retinitis Pigmentosahttps://modernod.com/news/ema-grants-two-product-designations-to-janssens-rpgr-gene-therapy-for-x-linked-retinitis-pigmentosa/2477338/The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene t
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseaseshttps://modernod.com/news/exonate-announces-collaboration-with-janssen-to-develop-a-new-eye-drop-for-the-treatment-of-retinal-vascular-diseases/2477223/Exonate, an early stage biotechnology company, announced that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development scientists to develop an